<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40388782</article-id><article-id pub-id-type="pmc">PMC12091589</article-id>
<article-id pub-id-type="publisher-id">MD-D-24-12443</article-id><article-id pub-id-type="art-access-id">00063</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000042398</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="heading"><subject>5000</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>A latent profile analysis of self-regulatory fatigue and its relationship with activation in patients receiving chemotherapy for breast carcinoma: An observational study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Ying</given-names></name><degrees>MM</degrees><email>onlyyangying@163.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Jing</given-names></name><degrees>MM</degrees><email>18782621896@163.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yina</given-names></name><degrees>MM</degrees><email>Na1518645620@163.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-0039-2119</contrib-id><name><surname>Li</surname><given-names>Li</given-names></name><degrees>MM</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Nursing Department, North Sichuan Medical College, Nanchong, China.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Li Li, Nursing Department, North Sichuan Medical College, Nanchong, China (e-mail: <email xlink:href="lilinsmc@163.com">lilinsmc@163.com</email>).</corresp></author-notes><pub-date pub-type="collection"><day>16</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2025</year></pub-date><volume>104</volume><issue>20</issue><elocation-id>e42398</elocation-id><history><date date-type="received"><day>13</day><month>10</month><year>2024</year></date><date date-type="received"><day>22</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="medi-104-e42398.pdf"/><abstract><p>This study explores the profiles of self-regulatory fatigue (SRF) in patients with breast cancer who received chemotherapy and their influencing factors and to analyze the relationships between these profiles and patient activation. A total of 315 individuals with breast cancer who received chemotherapy were chosen using convenience sampling between January and April 2024, and a cross-sectional survey was conducted, comprising a self-administered basic information questionnaire, the SRF Scale, and the Patient Activation Measure. SRF profiles were identified utilizing latent profile analysis, and factors that might influence the SRF profiles identified were analyzed employing the chi-square test and multiple regression analysis. Further, differences in activation among patients with the identified SRF profiles were assessed using an analysis of variance. The SRF of patients with mammary carcinoma receiving chemotherapy could be divided into 3 potential profiles: a high SRF, cognitively weakened group (29.2%), a moderate SRF, borderline group (46.7%), and a low SRF, behavioral stabilization group (24.1%). Medical payment method, disease duration, disease stage, number of chemotherapy-related symptoms, and whether or not the patient had undergone surgery for breast cancer were factors associated with patient SRF (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.05). The 3 potential SRF profiles showed notable variations in patient activation levels (<italic toggle="yes">F&#x02005;</italic>=&#x02005;83.707, <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.001). SRF was categorized into 3 profiles in individuals with mammary carcinoma undergoing chemotherapy. Healthcare professionals should focus on patients with low income, long disease duration, advanced disease stage, many chemotherapy-related symptoms, and who have undergone breast cancer surgery. In addition, SRF is closely related to patient activation, suggesting that interventions should be targeted based on these different SRF profiles to improve patient activation.</p></abstract><kwd-group><kwd>breast carcinoma</kwd><kwd>chemotherapy</kwd><kwd>latent profile analysis</kwd><kwd>patient activation</kwd><kwd>self-regulatory fatigue</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>
1. Introduction</title><p>According to the Global Cancer Statistics report, the tally of newly diagnosed occurrences of breast carcinoma in women reached approximately 2.3 million in 2022, accounting for 11.6% of all new neoplasm cases, second only to lung carcinoma in terms of prevalence.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> It was also estimated that female breast cancer was among the top 5 malignant tumors in China.<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> Chemotherapy is an important part of breast cancer treatment, as it improves patient survival rates. However, chemotherapy also has side reactions, including gastrointestinal toxicity, cardiotoxicity, peripheral neuropathy, and skin changes.<sup>[<xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R6" ref-type="bibr">6</xref>]</sup> Treatment cycles for breast cancer are long, and the toxic side effects of chemotherapy place patients in a state of chronic physical and mental stress. Most patients with breast cancer are women. Influenced by traditional Chinese thinking, women take more responsibility for taking care of their families and family members, and they need to continue to take care of the needs of their families and family members while undergoing treatment, which brings them additional psychological and emotional burdens, depletes their self-regulatory resources, and impairs their self-regulatory ability, which may lead to self-regulatory fatigue (SRF) in such patients. SRF refers to the overconsumption of self-control resources, resulting in decreased self-regulatory ability and a weakened willingness to control oneself.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> According to the self-control power model,<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> the higher the level of SRF experienced by an individual, the more self-control energy is lost, and the less self-control the person has, where self-control involves the regulation of one&#x02019;s impulses, desires, and emotions, and is crucial in achieving predetermined goals or conforming to socially normative behaviors.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup></p><p>A variety of personal and environmental factors can impose physical and psychological burdens on patients, resulting in a high depletion of self-control resources, difficulty in effectively managing cognition and emotions, and growth of negative thinking, which in turn affect patient activation.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> Patient activation refers to the extent to which patients are likely to be proactive in self-health management and the cognition, skills, actions, and beliefs they possess for self-health management.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> Patient activation is crucial for evaluating self-management potential and health outcomes.<sup>[<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref>]</sup> Research has shown that individuals with SRF have reduced amygdala function.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> The amygdala is responsible for generating, recognizing, and regulating emotions. This indicates that patients with SRF may struggle to control their emotions, which could also impact patients&#x02019; motivation for self-management. In October 2023, the Office of Health Emergencies in China emphasized in its document on cancer prevention and control the importance of advocating a healthy lifestyle, spreading health knowledge, and encouraging people to actively participate in cancer prevention and treatment. This highlights the significance of individuals taking the initiative to maintain their own health.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> Improving patient activation promotes good health behaviors, optimizes disease prognosis, enhances the quality and efficiency of nursing services, and reduces unnecessary medical expenditure.<sup>[<xref rid="R16" ref-type="bibr">16</xref>&#x02013;<xref rid="R18" ref-type="bibr">18</xref>]</sup></p><p>To date, studies on SRF have focused on nursing students,<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup> patients with coronary heart disease,<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> and individuals undergoing peritoneal dialysis,<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> while there have been few studies on the SRF status of individuals diagnosed with mammary carcinoma and treated with chemotherapy and the factors affecting it. Further, neither the relationship between SRF and patient activation nor the activation characteristics of individuals with different SRF profiles among patients with breast cancer undergoing chemotherapy have been comprehensively explored, and understanding these relationships will be crucial for improving patient SRF, increasing their activation and promoting high quality cancer control and treatment. Existing studies mostly use scale scores as the judgment criterion, with less consideration of inter-individual differences. Latent profile analysis can better understand group heterogeneity by analyzing the scores of scale entries or dimensions, revealing potential characteristics or attributes of the group, and categorizing them. Therefore, this study used latent profile analysis to analyze different categories of SRF in breast cancer patients undergoing chemotherapy, to explore the factors associated with these categories, and to investigate the relationship between SRF and patient activation.</p></sec><sec sec-type="methods"><title>
2. Materials and methods</title><sec sec-type="subjects"><title>
2.1. Ethical statement and patient consent</title><p>The Ethics Committee of the Affiliated Hospital of North Sichuan Medical College has granted its approval for this research (Approval Number: 2024ER119-1). Consent was obtained from all respondents before the study commenced.</p></sec><sec><title>
2.2. Participants</title><p>In this study, patients with breast cancer who received chemotherapy from January to April 2024 in 2 tertiary hospitals in Sichuan Province, China, were selected by convenience sampling. Criteria for inclusion were as stated below: individuals diagnosed with mammary carcinoma by pathologic examination, undergoing chemotherapy, normal communication ability, and voluntary engagement in this investigation. Criteria for exclusion were as stated below: additional malignancies coexisting at the same time and mental disorders. The sample size was calculated based on 5 to 10 times the number of variables, with a 20% allowance for ineligible surveys included in the calculation. This investigation included 15 variables (13 general information items, 1 SRF item, and 1 patient activation item), and the necessary sampling range was estimated to vary from 94 to 188 participants. A sum of 320 patients took part in the research and 5 patients withdrew, resulting in the inclusion of 315 eligible patients.</p></sec><sec><title>
2.3. Measures</title><sec><title>
2.3.1. Basic information questionnaire</title><p>This questionnaire was employed to gather sociodemographic and disease-related information from patients. Sociodemographic data included occupational status, marital status, medical payment method, etc. Disease-related information included disease duration, disease stage, number of chemotherapy-related symptoms, presence of chronic disease, and whether or not the patient had undergone surgery for breast cancer.</p></sec><sec><title>
2.3.2. Self-regulatory fatigue scale</title><p>The original scale was developed by Nes.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> The Chinese version of the scale, translated by Wang,<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> was used in this study. SRF-S contains 3 dimensions, with a total of 16 items, as follows: a cognition dimension (6 items), an emotion dimension (5 items), and a behavior dimension (5 items). The SRF-S assessment uses a 5-point Likert scale, ranging from 1 (strongly disagree) to 5 (strongly agree). A higher score reflects a stronger degree of SRF. In this research, the internal consistency of this scale was measured at 0.906 using Cronbach alpha coefficient.</p></sec><sec sec-type="subjects"><title>
2.3.3. Patient activation measure</title><p>The original PAM scale was developed by Hibbard.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> The Chinese version of the scale, translated by Hong,<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> was utilized in the investigation. PAM is scored using a Likert 5-point scale, ranging from 0 (not applicable) to 4 (strongly agree), and the raw scores are converted to a scale from 0 to 100. Higher scores reflect a higher level of patient activation. Based on PAM scores, patient activation was categorized into 4 levels, as follows: first level (low level), total score&#x02005;&#x02264;&#x02005;47; second level (low and medium level), 47.1 to 55.1; third level (medium level), 55.2 to 67.0; and fourth level (high level),&#x02005;&#x02265;&#x02005;67.1. In this research, the internal consistency of this scale was measured at 0.778 using Cronbach alpha coefficient.</p></sec></sec><sec><title>
2.4. Data collection</title><p>Data were collected before patients had completed their previous course of chemotherapy and were about to start their next course of chemotherapy drugs. At the time of the survey, patients had completed at least 1 course of chemotherapy. Using an anonymous survey approach, the researcher clarified the aim and specifics of the research to eligible participants and distributed the questionnaire after securing their approval. The researcher explained the questionnaire notes to the respondents with unified instruction, and the respondents completed the questionnaire independently. If the respondents asked for clarification of any entries, they were promptly explained. The researcher collected and checked the questionnaires on the spot and then evaluated them after confirming no errors.</p></sec><sec><title>
2.5. Data analysis</title><p>Potential SRF profiles were determined using Mplus 8.3 software, with the 3-dimensional SRF-S scores as indicators. The optimal classification was determined based on a series of fitted information indices, including log-likelihood value, Akaike information criterion (AIC), Bayesian information criterion (BIC), adjusted BIC (aBIC), entropy of information, Bootstrapped Likelihood Ratio Test (BLRT), and Lo-Mendell-Rubin test (LMRT). AIC, BIC, and aBIC values were minimized, and entropy values closest to 1 were selected (where values&#x02005;&#x02265;&#x02005;0.8 indicated 90% categorization accuracy), along with LMRT and BLRT reaching the significance level.<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> IBM SPSS 26.0 was used for descriptive statistical analysis. Categorical variables are expressed as frequency (percentage), and continuous variables as mean and standard deviation. The chi-square test was used for the univariate analysis of potential SRF profiles; factors with <italic toggle="yes">P&#x02005;&#x0003c;&#x02005;</italic>.05 in the univariate analysis were included in the multivariate logistic regression analysis. Analysis of variance was used for between-group comparisons of patient activation scores. In this study, differences were considered statistically significant at <italic toggle="yes">P&#x02005;&#x0003c;&#x02005;</italic>.05.</p></sec></sec><sec sec-type="results"><title>
3. Results</title><sec sec-type="methods"><title>
3.1. Common method bias test</title><p>In the present research, Harman single-factor test<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> results indicated 7 distinct factors with eigenvalues exceeding 1. Furthermore, the cumulative variance accounted for by the first factor amounted to 29.984%, which fell short of the critical threshold of 40%. These findings suggest that common method bias did not significantly influence the current study.</p></sec><sec><title>
3.2. Potential SRF profiles</title><p>Latent profile analysis was performed based on the 3 dimensions of SRF-S, 1 to 5 potential profile models were constructed, and the specific results have been detailed in Table <xref rid="T1" ref-type="table">1</xref>. In models 1 to 4, the values of AIC, BIC, and aBIC sequentially decreased. However, in model 5, while the values of AIC were decreasing, those of BIC and aBIC appeared to increase, and the <italic toggle="yes">P</italic>-values of LMR and BLRT were not significant (<italic toggle="yes">P</italic>&#x02005;&#x0003e;&#x02005;.05). The AIC, BIC, and aBIC values for Model 4 are smaller than those of AIC, BIC, and aBIC for Model 3, indicating a better model fit for Model 4. However, the entropy value for Model 4 is smaller than that of Model 3, indicating that Model 3 has a higher classification accuracy. According to Table <xref rid="T2" ref-type="table">2</xref>, the average probability of belonging to each category in Model 3 is 0.905, 0.952, and 0.941, respectively, indicating that the results are highly reliable. Meanwhile, considering the simplicity of classification, we chose Model 3 as the optimal model. Profile 1 had high scores on all dimensions, with the highest score on the cognitive dimension, therefore it was named the high SRF, cognitively weakened group, a total of 92 cases (29.2%) were included in this profile. Profile 2 included scores between those of profiles 1 and 3, therefore it was named the moderate SRF, borderline group, and included 147 cases (46.7%). Patients with profile 3 had low scores on all dimensions, with the lowest scores on the behavioral dimension, therefore, patients with this profile were referred to as the low SRF, behavioral stabilization group, and comprised 76 cases (24.1%). These results are summarized in Table <xref rid="T3" ref-type="table">3</xref> and Figure <xref rid="F1" ref-type="fig">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Results of potential profiles of SRF.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Model</th><th align="center" rowspan="1" colspan="1">K</th><th align="center" rowspan="1" colspan="1">Log (L)</th><th align="center" rowspan="1" colspan="1">AIC</th><th align="center" rowspan="1" colspan="1">BIC</th><th align="center" rowspan="1" colspan="1">aBIC</th><th align="center" rowspan="1" colspan="1">Entropy</th><th align="center" rowspan="1" colspan="1">LMR</th><th align="center" rowspan="1" colspan="1">BLRT</th><th align="center" rowspan="1" colspan="1">Potential profile proportion</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">&#x02212;2297.688</td><td align="center" rowspan="1" colspan="1">4607.376</td><td align="center" rowspan="1" colspan="1">4629.892</td><td align="center" rowspan="1" colspan="1">4610.861</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">&#x02212;2093.133</td><td align="center" rowspan="1" colspan="1">4206.265</td><td align="center" rowspan="1" colspan="1">4243.791</td><td align="center" rowspan="1" colspan="1">4212.074</td><td align="center" rowspan="1" colspan="1">0.839</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.394/0.606</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">&#x02212;2010.993</td><td align="center" rowspan="1" colspan="1">4049.985</td><td align="center" rowspan="1" colspan="1">4102.521</td><td align="center" rowspan="1" colspan="1">4058.117</td><td align="center" rowspan="1" colspan="1">0.839</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.292/0.467/0.241</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">&#x02212;1984.335</td><td align="center" rowspan="1" colspan="1">4004.670</td><td align="center" rowspan="1" colspan="1">4072.216</td><td align="center" rowspan="1" colspan="1">4015.125</td><td align="center" rowspan="1" colspan="1">0.833</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.406/0.232/0.257/0.105</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">&#x02212;1979.718</td><td align="center" rowspan="1" colspan="1">4003.436</td><td align="center" rowspan="1" colspan="1">4085.993</td><td align="center" rowspan="1" colspan="1">4016.215</td><td align="center" rowspan="1" colspan="1">0.775</td><td align="center" rowspan="1" colspan="1">0.620</td><td align="center" rowspan="1" colspan="1">0.667</td><td align="center" rowspan="1" colspan="1">0.225/0.086/0.337/0.251/0.102</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>aBIC = adjusted Bayesian information criterion, AIC&#x02005;=&#x02005;Akaike information criterion, BIC&#x02005;=&#x02005;Bayesian information criterion, BLRT = Bootstrapped Likelihood Ratio Test, LMR&#x02005;=&#x02005;Lo-Mendell-Rubin test, Log(L) = log-likelihood, SRF = self-regulatory fatigue.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Average probability of each potential category.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Latent class</th><th align="center" rowspan="1" colspan="1">1</th><th align="center" rowspan="1" colspan="1">2</th><th align="center" rowspan="1" colspan="1">3</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.905</td><td align="center" rowspan="1" colspan="1">0.063</td><td align="center" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0.048</td><td align="center" rowspan="1" colspan="1">0.952</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0.059</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.941</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Means and standard deviations of the total SRF scores and scores on each dimension for different potential profiles.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">High SRF, cognitively weakened group (n&#x02005;=&#x02005;92)</th><th align="center" rowspan="1" colspan="1">Moderate SRF, borderline group (n&#x02005;=&#x02005;147)</th><th align="center" rowspan="1" colspan="1">Low SRF, behavioral stabilization group (n&#x02005;=&#x02005;76)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total score, M (SD)</td><td align="center" rowspan="1" colspan="1">60.37 (3.46)</td><td align="center" rowspan="1" colspan="1">50.19 (2.79)</td><td align="center" rowspan="1" colspan="1">41.13 (2.68)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cognitive, M (SD)</td><td align="center" rowspan="1" colspan="1">24.08 (1.92)</td><td align="center" rowspan="1" colspan="1">20.47 (1.69)</td><td align="center" rowspan="1" colspan="1">16.59 (1.47)</td></tr><tr><td align="left" rowspan="1" colspan="1">Emotional, M (SD)</td><td align="center" rowspan="1" colspan="1">17.85 (1.27)</td><td align="center" rowspan="1" colspan="1">14.77 (1.22)</td><td align="center" rowspan="1" colspan="1">12.37 (1.19)</td></tr><tr><td align="left" rowspan="1" colspan="1">Behavioral, M (SD)</td><td align="center" rowspan="1" colspan="1">18.45 (1.68)</td><td align="center" rowspan="1" colspan="1">14.95 (1.57)</td><td align="center" rowspan="1" colspan="1">12.17 (1.16)</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>SRF&#x02005;=&#x02005;self-regulatory fatigue.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1.</label><caption><p>Mean scores of dimensions for SRF profiles. SRF = self-regulatory fatigue.</p></caption><graphic xlink:href="medi-104-e42398-g001" position="float"/></fig></sec><sec><title>
3.3. Univariate analysis of factors associated with SRF profiles</title><p>Univariate analysis showed statistically significant differences among patients with the 3 SRF profiles in terms of age, monthly income (Chinese Yuan), medical payment method, disease duration, disease stage, number of chemotherapy-related symptoms, and whether or not they had undergone surgery for breast cancer (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.05) (Table <xref rid="T4" ref-type="table">4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Univariate analysis of factors associated with SRF profiles.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">High SRF, cognitively weakened group (n&#x02005;=&#x02005;92)</th><th align="center" rowspan="1" colspan="1">Moderate SRF, borderline group (n&#x02005;=&#x02005;147)</th><th align="center" rowspan="1" colspan="1">Low SRF, behavioral stabilization group (n&#x02005;=&#x02005;76)</th><th align="center" rowspan="1" colspan="1">&#x003c7;<sup>2</sup></th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Age (yr)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;18 to 45</td><td align="center" rowspan="1" colspan="1">12 (13.0%)</td><td align="center" rowspan="1" colspan="1">27 (18.4%)</td><td align="center" rowspan="1" colspan="1">24 (31.6%)</td><td align="center" rowspan="1" colspan="1">9.396</td><td align="center" rowspan="1" colspan="1">.009</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;45</td><td align="center" rowspan="1" colspan="1">80 (87.0%)</td><td align="center" rowspan="1" colspan="1">120 (81.6%)</td><td align="center" rowspan="1" colspan="1">52 (68.4%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Place of residence</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Rural</td><td align="center" rowspan="1" colspan="1">53 (57.6%)</td><td align="center" rowspan="1" colspan="1">68 (46.3%)</td><td align="center" rowspan="1" colspan="1">45 (59.2%)</td><td align="center" rowspan="2" colspan="1">4.629</td><td align="center" rowspan="2" colspan="1">.099</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Urban</td><td align="center" rowspan="1" colspan="1">39 (42.4%)</td><td align="center" rowspan="1" colspan="1">79 (53.7%)</td><td align="center" rowspan="1" colspan="1">31 (40.8%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Occupational status</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Employed</td><td align="center" rowspan="1" colspan="1">60 (65.2%)</td><td align="center" rowspan="1" colspan="1">91 (61.9%)</td><td align="center" rowspan="1" colspan="1">51 (67.1%)</td><td align="center" rowspan="2" colspan="1">0.656</td><td align="center" rowspan="2" colspan="1">.720</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Unemployed</td><td align="center" rowspan="1" colspan="1">32 (34.8%)</td><td align="center" rowspan="1" colspan="1">56 (38.1%)</td><td align="center" rowspan="1" colspan="1">25 (32.9%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Marital status</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="center" rowspan="1" colspan="1">5 (5.4%)</td><td align="center" rowspan="1" colspan="1">17 (11.6%)</td><td align="center" rowspan="1" colspan="1">8 (10.5)</td><td align="center" rowspan="2" colspan="1">2.584</td><td align="center" rowspan="2" colspan="1">.275</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Married</td><td align="center" rowspan="1" colspan="1">87 (94.6%)</td><td align="center" rowspan="1" colspan="1">130 (88.4%)</td><td align="center" rowspan="1" colspan="1">68 (89.5%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Education level</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Primary school</td><td align="center" rowspan="1" colspan="1">35 (38.0%)</td><td align="center" rowspan="1" colspan="1">59 (40.1%)</td><td align="center" rowspan="1" colspan="1">25 (32.9%)</td><td align="center" rowspan="4" colspan="1">2.846</td><td align="center" rowspan="4" colspan="1">.828</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Junior high school</td><td align="center" rowspan="1" colspan="1">37 (40.2%)</td><td align="center" rowspan="1" colspan="1">49 (33.3%)</td><td align="center" rowspan="1" colspan="1">28 (36.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Senior high school</td><td align="center" rowspan="1" colspan="1">15 (16.3%)</td><td align="center" rowspan="1" colspan="1">27 (18.4%)</td><td align="center" rowspan="1" colspan="1">16 (21.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;College and above</td><td align="center" rowspan="1" colspan="1">5 (5.4%)</td><td align="center" rowspan="1" colspan="1">12 (8.2%)</td><td align="center" rowspan="1" colspan="1">7 (9.2%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Monthly income (Chinese Yuan)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02264;2000</td><td align="center" rowspan="1" colspan="1">35 (38.0%)</td><td align="center" rowspan="1" colspan="1">21 (14.3%)</td><td align="center" rowspan="1" colspan="1">8 (10.5%)</td><td align="center" rowspan="4" colspan="1">49.596</td><td align="center" rowspan="4" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2001 to 3000</td><td align="center" rowspan="1" colspan="1">34 (37.0%)</td><td align="center" rowspan="1" colspan="1">57 (38.8%)</td><td align="center" rowspan="1" colspan="1">14 (18.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3001 to 4000</td><td align="center" rowspan="1" colspan="1">18 (19.6%)</td><td align="center" rowspan="1" colspan="1">53 (36.1%)</td><td align="center" rowspan="1" colspan="1">35 (46.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;4000</td><td align="center" rowspan="1" colspan="1">5 (5.4%)</td><td align="center" rowspan="1" colspan="1">16 (10.9%)</td><td align="center" rowspan="1" colspan="1">19 (25.0%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Medical payment method</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Urban and rural resident medical insurance</td><td align="center" rowspan="1" colspan="1">82 (89.1%)</td><td align="center" rowspan="1" colspan="1">81 (55.1%)</td><td align="center" rowspan="1" colspan="1">26 (34.2%)</td><td align="center" rowspan="2" colspan="1">55.060</td><td align="center" rowspan="2" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Urban employee medical insurance</td><td align="center" rowspan="1" colspan="1">10 (10.9%)</td><td align="center" rowspan="1" colspan="1">66 (44.9%)</td><td align="center" rowspan="1" colspan="1">50 (65.8%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Disease duration</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;3 mo</td><td align="center" rowspan="1" colspan="1">24 (26.1%)</td><td align="center" rowspan="1" colspan="1">49 (33.3%)</td><td align="center" rowspan="1" colspan="1">53 (69.7%)</td><td align="center" rowspan="3" colspan="1">46.273</td><td align="center" rowspan="3" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3 to 6 mo</td><td align="center" rowspan="1" colspan="1">31 (33.7%)</td><td align="center" rowspan="1" colspan="1">61 (41.5%)</td><td align="center" rowspan="1" colspan="1">18 (23.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;6 mo</td><td align="center" rowspan="1" colspan="1">37 (40.2%)</td><td align="center" rowspan="1" colspan="1">37 (25.2%)</td><td align="center" rowspan="1" colspan="1">5 (6.6%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Disease stage</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;I</td><td align="center" rowspan="1" colspan="1">6 (6.5%)</td><td align="center" rowspan="1" colspan="1">29 (19.7%)</td><td align="center" rowspan="1" colspan="1">26 (34.2%)</td><td align="center" rowspan="3" colspan="1">60.044</td><td align="center" rowspan="3" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;II</td><td align="center" rowspan="1" colspan="1">33 (35.9%)</td><td align="center" rowspan="1" colspan="1">83 (56.5%)</td><td align="center" rowspan="1" colspan="1">44 (57.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;III to IV</td><td align="center" rowspan="1" colspan="1">53 (57.6%)</td><td align="center" rowspan="1" colspan="1">35 (23.8%)</td><td align="center" rowspan="1" colspan="1">6 (7.9%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Course of chemotherapy</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1 to 2</td><td align="center" rowspan="1" colspan="1">28 (30.4%)</td><td align="center" rowspan="1" colspan="1">51 (34.7%)</td><td align="center" rowspan="1" colspan="1">34 (44.7%)</td><td align="center" rowspan="3" colspan="1">5.412</td><td align="center" rowspan="1" colspan="1">.248</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3 to 5</td><td align="center" rowspan="1" colspan="1">42 (45.7%)</td><td align="center" rowspan="1" colspan="1">71 (48.3%)</td><td align="center" rowspan="1" colspan="1">28 (36.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;6 to 8</td><td align="center" rowspan="1" colspan="1">22 (23.9%)</td><td align="center" rowspan="1" colspan="1">25 (17.0%)</td><td align="center" rowspan="1" colspan="1">14 (18.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Number of chemotherapy-related symptoms</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02264;1</td><td align="center" rowspan="1" colspan="1">15 (16.3%)</td><td align="center" rowspan="1" colspan="1">54 (36.7%)</td><td align="center" rowspan="1" colspan="1">53 (69.7%)</td><td align="center" rowspan="3" colspan="1">66.380</td><td align="center" rowspan="3" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2 to 3</td><td align="center" rowspan="1" colspan="1">41 (44.6%)</td><td align="center" rowspan="1" colspan="1">72 (49.0%)</td><td align="center" rowspan="1" colspan="1">19 (25.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;4</td><td align="center" rowspan="1" colspan="1">36 (39.1%)</td><td align="center" rowspan="1" colspan="1">21 (14.3%)</td><td align="center" rowspan="1" colspan="1">4 (5.3%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Presence of chronic diseases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">21 (22.8%)</td><td align="center" rowspan="1" colspan="1">25 (17.0%)</td><td align="center" rowspan="1" colspan="1">13 (17.1%)</td><td align="center" rowspan="2" colspan="1">1.433</td><td align="center" rowspan="2" colspan="1">.489</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">71 (77.2%)</td><td align="center" rowspan="1" colspan="1">122 (83.0%)</td><td align="center" rowspan="1" colspan="1">63 (82.9%)</td></tr><tr><td align="left" colspan="6" rowspan="1">Whether or not the patient had undergone surgery for breast cancer</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">49 (53.3%)</td><td align="center" rowspan="1" colspan="1">105 (71.4%)</td><td align="center" rowspan="1" colspan="1">45 (59.2%)</td><td align="center" rowspan="2" colspan="1">8.705</td><td align="center" rowspan="2" colspan="1">.013</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">43 (46.7%)</td><td align="center" rowspan="1" colspan="1">42 (28.6%)</td><td align="center" rowspan="1" colspan="1">31 (40.8%)</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>SRF&#x02005;=&#x02005;self-regulatory fatigue</p></fn></table-wrap-foot></table-wrap></sec><sec><title>
3.4. Multivariate analysis of factors associated with SRF profiles</title><p>Multivariate logistic regression analyses were conducted using the 3 SRF profiles as dependent variables and age, monthly income (Chinese Yuan), medical payment method, disease duration, disease stage, number of chemotherapy-related symptoms, and whether or not breast cancer surgery was performed as independent variables. The results demonstrated that medical payment method, disease duration, disease stage, number of chemotherapy-related symptoms, and whether or not the patient had undergone surgery for breast cancer were factors potentially influencing SRF profiles (Table <xref rid="T5" ref-type="table">5</xref>).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Multivariate analysis of factors associated with SRF profiles.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">B</italic>
</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1">Wald</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">High SRF, cognitively weakened group VS Low SRF, behavioral stabilization group<xref rid="tab5fn2" ref-type="table-fn">*</xref></td></tr><tr><td align="left" colspan="7" rowspan="1">&#x02003;Medical payment method</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Urban and rural resident medical insurance</td><td align="center" rowspan="1" colspan="1">1.920</td><td align="center" rowspan="1" colspan="1">0.498</td><td align="center" rowspan="1" colspan="1">14.840</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" rowspan="1" colspan="1">6.823</td><td align="center" rowspan="1" colspan="1">(2.568&#x02013;18.125)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Urban employee medical insurance<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">&#x02003;Disease duration</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;3 mo</td><td align="center" rowspan="1" colspan="1">&#x02212;1.968</td><td align="center" rowspan="1" colspan="1">0.643</td><td align="center" rowspan="1" colspan="1">9.355</td><td align="center" rowspan="1" colspan="1">.002</td><td align="center" rowspan="1" colspan="1">0.140</td><td align="center" rowspan="1" colspan="1">(0.040&#x02013;0.493)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3 to 6 mo</td><td align="center" rowspan="1" colspan="1">&#x02212;1.368</td><td align="center" rowspan="1" colspan="1">0.655</td><td align="center" rowspan="1" colspan="1">4.365</td><td align="center" rowspan="1" colspan="1">.037</td><td align="center" rowspan="1" colspan="1">0.255</td><td align="center" rowspan="1" colspan="1">(0.071&#x02013;0.919)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003e;6 mo<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">&#x02003;Disease stage</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;I</td><td align="center" rowspan="1" colspan="1">&#x02212;3.147</td><td align="center" rowspan="1" colspan="1">0.769</td><td align="center" rowspan="1" colspan="1">16.752</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" rowspan="1" colspan="1">0.043</td><td align="center" rowspan="1" colspan="1">(0.010&#x02013;0.194)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;II</td><td align="center" rowspan="1" colspan="1">&#x02212;2.024</td><td align="center" rowspan="1" colspan="1">0.598</td><td align="center" rowspan="1" colspan="1">11.465</td><td align="center" rowspan="1" colspan="1">.001</td><td align="center" rowspan="1" colspan="1">0.132</td><td align="center" rowspan="1" colspan="1">(0.041&#x02013;0.426)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;III to IV<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">&#x02003;Number of chemotherapy-related symptoms</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02264;1</td><td align="center" rowspan="1" colspan="1">&#x02212;2.149</td><td align="center" rowspan="1" colspan="1">0.710</td><td align="center" rowspan="1" colspan="1">9.168</td><td align="center" rowspan="1" colspan="1">.002</td><td align="center" rowspan="1" colspan="1">0.117</td><td align="center" rowspan="1" colspan="1">(0.029&#x02013;0.469)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;2 to 3</td><td align="center" rowspan="1" colspan="1">&#x02212;0.576</td><td align="center" rowspan="1" colspan="1">0.684</td><td align="center" rowspan="1" colspan="1">0.709</td><td align="center" rowspan="1" colspan="1">.400</td><td align="center" rowspan="1" colspan="1">0.562</td><td align="center" rowspan="1" colspan="1">(0.147&#x02013;2.150)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02265;4<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">Moderate SRF, borderline group VS Low SRF, behavioral stabilization group<xref rid="tab5fn2" ref-type="table-fn">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Disease duration</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;3 mo</td><td align="center" rowspan="1" colspan="1">&#x02212;1.551</td><td align="center" rowspan="1" colspan="1">0.558</td><td align="center" rowspan="1" colspan="1">7.728</td><td align="center" rowspan="1" colspan="1">.005</td><td align="center" rowspan="1" colspan="1">0.212</td><td align="center" rowspan="1" colspan="1">(0.071&#x02013;0.633)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3 to 6 mo</td><td align="center" rowspan="1" colspan="1">&#x02212;0.695</td><td align="center" rowspan="1" colspan="1">0.588</td><td align="center" rowspan="1" colspan="1">1.399</td><td align="center" rowspan="1" colspan="1">.237</td><td align="center" rowspan="1" colspan="1">0.499</td><td align="center" rowspan="1" colspan="1">(0.158&#x02013;1.579)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003e;6 mo<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Disease stage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;I</td><td align="center" rowspan="1" colspan="1">&#x02212;1.568</td><td align="center" rowspan="1" colspan="1">0.606</td><td align="center" rowspan="1" colspan="1">6.692</td><td align="center" rowspan="1" colspan="1">.010</td><td align="center" rowspan="1" colspan="1">0.208</td><td align="center" rowspan="1" colspan="1">(0.063&#x02013;0.684)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;II</td><td align="center" rowspan="1" colspan="1">&#x02212;0.965</td><td align="center" rowspan="1" colspan="1">0.548</td><td align="center" rowspan="1" colspan="1">3.107</td><td align="center" rowspan="1" colspan="1">.078</td><td align="center" rowspan="1" colspan="1">0.381</td><td align="center" rowspan="1" colspan="1">(0.130&#x02013;1.114)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;III to IV<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">&#x02003;Whether or not the patient had undergone surgery for breast cancer</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">0.770</td><td align="center" rowspan="1" colspan="1">0.370</td><td align="center" rowspan="1" colspan="1">4.322</td><td align="center" rowspan="1" colspan="1">0.038</td><td align="center" rowspan="1" colspan="1">2.159</td><td align="center" rowspan="1" colspan="1">(1.045&#x02013;4.461)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;No<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">High SRF, cognitively weakened group VS Moderate SRF, borderline group<xref rid="tab5fn4" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td align="left" colspan="7" rowspan="1">&#x02003;Medical payment method</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Urban and rural resident medical insurance</td><td align="center" rowspan="1" colspan="1">1.505</td><td align="center" rowspan="1" colspan="1">0.410</td><td align="center" rowspan="1" colspan="1">13.469</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" rowspan="1" colspan="1">4.503</td><td align="center" rowspan="1" colspan="1">(2.016&#x02013;10.059)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Urban employee medical insurance<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">&#x02003;Disease stage</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;I</td><td align="center" rowspan="1" colspan="1">&#x02212;1.578</td><td align="center" rowspan="1" colspan="1">0.571</td><td align="center" rowspan="1" colspan="1">7.626</td><td align="center" rowspan="1" colspan="1">.006</td><td align="center" rowspan="1" colspan="1">0.206</td><td align="center" rowspan="1" colspan="1">(0.067&#x02013;0.633)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;II</td><td align="center" rowspan="1" colspan="1">&#x02212;1.059</td><td align="center" rowspan="1" colspan="1">0.354</td><td align="center" rowspan="1" colspan="1">8.950</td><td align="center" rowspan="1" colspan="1">.003</td><td align="center" rowspan="1" colspan="1">0.347</td><td align="center" rowspan="1" colspan="1">(0.173&#x02013;0.694)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;III to IV<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">&#x02003;Number of chemotherapy-related symptoms</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02264;1</td><td align="center" rowspan="1" colspan="1">&#x02212;1.170</td><td align="center" rowspan="1" colspan="1">0.471</td><td align="center" rowspan="1" colspan="1">6.175</td><td align="center" rowspan="1" colspan="1">.013</td><td align="center" rowspan="1" colspan="1">0.310</td><td align="center" rowspan="1" colspan="1">(0.123&#x02013;0.781)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;2 to 3</td><td align="center" rowspan="1" colspan="1">&#x02212;0.636</td><td align="center" rowspan="1" colspan="1">0.384</td><td align="center" rowspan="1" colspan="1">2.739</td><td align="center" rowspan="1" colspan="1">.098</td><td align="center" rowspan="1" colspan="1">0.529</td><td align="center" rowspan="1" colspan="1">(0.249&#x02013;1.124)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02265;4<xref rid="tab5fn3" ref-type="table-fn">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>SRF&#x02005;=&#x02005;self-regulatory fatigue.</p></fn><fn fn-type="other" id="tab5fn2"><label>*</label><p> Low SRF, behavioral stabilization group as a reference.</p></fn><fn fn-type="other" id="tab5fn3"><label>&#x02020;</label><p> Reference category.</p></fn><fn fn-type="other" id="tab5fn4"><label>&#x02021;</label><p> Reference category. Moderate SRF, borderline group as a reference.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="subjects"><title>
3.5. Comparison of activation scores among patients with different SRF profiles</title><p>The mean (standard deviation) activation score of patients with breast cancer undergoing chemotherapy was 57.34 (8.82), which was at the third level overall, including 53 cases (16.8%) at the first level, 68 (21.6%) at the second level, 147 (46.7%) at the third level, and 47 (14.9%) at the fourth level. Comparisons of activation scores among patients with the 3 SRF profiles indicated that they differed significantly (<italic toggle="yes">P&#x02005;&#x0003c;&#x02005;</italic>.001) (Table <xref rid="T6" ref-type="table">6</xref>).</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Comparison of activation scores among patients with different SRF profiles.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">High SRF, cognitively weakened group (n&#x02005;=&#x02005;92)</th><th align="center" rowspan="1" colspan="1">Moderate SRF, borderline group (n&#x02005;=&#x02005;147)</th><th align="center" rowspan="1" colspan="1">Low SRF, behavioral stabilization group (n&#x02005;=&#x02005;76)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">F</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" rowspan="1" colspan="1">LSD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total patient activation scores, M (SD)</td><td align="center" rowspan="1" colspan="1">50.59 (6.99)</td><td align="center" rowspan="1" colspan="1">57.66 (7.55)</td><td align="center" rowspan="1" colspan="1">64.88 (6.44)</td><td align="center" rowspan="1" colspan="1">83.707</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td><td align="center" rowspan="1" colspan="1">Low SRF, behavioral stabilization group &#x0003e; Moderate SRF, borderline group<xref rid="tab6fn2" ref-type="table-fn">*</xref>,<break/>Low SRF, behavioral stabilization group &#x0003e; High SRF, cognitively weakened group<xref rid="tab6fn2" ref-type="table-fn">*</xref>, Moderate SRF, borderline group &#x0003e; High SRF, cognitively weakened group<xref rid="tab6fn2" ref-type="table-fn">*</xref></td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>SRF&#x02005;=&#x02005;self-regulatory fatigue.</p></fn><fn fn-type="other" id="tab6fn2"><label>*</label><p><italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.05.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>
4. Discussion</title><p>Three different potential categories of SRF were identified among patients with breast cancer undergoing chemotherapy. Medical payment method, disease duration, disease stage, number of chemotherapy-related symptoms, and whether or not the patient had undergone surgery for breast cancer were factors potentially influencing these SRF profiles. Further, comparison across SRF profiles indicated that they differed significantly according to patient activation score.</p><sec><title>
4.1. SRF heterogeneity among individuals with mammary carcinoma receiving chemotherapy</title><p>This study identified 3 SRF profiles in individuals with mammary carcinoma who received chemotherapy: a high SRF, cognitively weakened group; a moderate SRF, borderline group; and a low SRF, behavioral stabilization group. The high SRF, cognitively weakened group accounted for 29.2% of patients, who had higher scores on all dimensions of SRF-S than those with the other 2 profiles, with the highest scores on the cognitive dimensions, indicating that these patients had a heavier cognitive load. This may be due to the fact that illness and treatment not only make it difficult for patients to fulfill their family duties, but also increase financial pressure and caregiving needs, and patients are prone to guilt and self-blame, which leads to negative thoughts about their lives and interpersonal interactions.<sup>[<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>]</sup> Our data suggest that patients in this group represent a key concern and that clinical teams can implement targeted interventions, starting with factors that can positively influence SRF. The moderate SRF, borderline group included 46.7% of patients, which was the largest proportion. This may be because most of the subjects included in this investigation were young and middle-aged patients, consistent with the trend toward breast cancer incidence at a younger age in China.<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> This group of patients may have higher physical and mental energy reserves, greater recovery motivation, and better self-regulatory ability.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> However, due to the long duration of the disease and the fact that patients were at a critical stage of life, shouldering multiple responsibilities, such as family, work, etc., the majority of patients had moderate level SRF, suggesting that there remains room to improve SRF in this group of patients. Patients in the low SRF, behavioral stabilization group comprised 24.1% of total respondents. Our findings suggest that these patients had calmly accepted the reality of the disease and could effectively manage their behavior with less aggression. For this group, healthcare professionals should carefully assess their shortcomings and develop individualized strategies to help them maintain their low SRF levels.</p></sec><sec><title>
4.2. Factors influencing SRF profiles</title><sec sec-type="methods"><title>
4.2.1. Association of medical payment method with SRF</title><p>Our findings indicate that patients with urban and rural resident medical insurance were more prone to being a part of the high SRF, cognitively weakened group. This result is consistent with what Zhou reported.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> Breast cancer treatment is expensive. Individuals with urban and rural resident medical insurance are usually rural or urban residents with low incomes,<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> and the reimbursement rate is relatively low, placing a greater financial burden on patients&#x02019; families. The economic basis motivates self-health management, suggesting that healthcare professionals should develop appropriate treatment plans based on the patient&#x02019;s economic status to alleviate their financial stress as much as possible.</p></sec><sec><title>
4.2.2. Association of disease duration with SRF</title><p>Our data show that patients with shorter disease duration were more readily a part of the low SRF, behavioral stabilization group. Relative to those with a short disease duration, individuals with a longer disease duration experience more hospitalizations, longer periods of self-regulation, and use up more self-control resources as the disease progresses. Thus, these patients suffer from more severe SRF.<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> It is recommended that healthcare professionals focus on patients with breast cancer undergoing chemotherapy who have longer disease duration, providing them with psychological therapy and assisting them in establishing a positive social support system to enhance their psychological resilience.<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> Such approaches will enable patients to adopt effective coping strategies and decrease the depletion of their psychological resources.</p></sec><sec><title>
4.2.3. Association of disease stage with SRF</title><p>The results of the study showed that patients with later disease staging were more likely to be in the moderate SRF, borderline group, or high SRF, cognitively weakened group. A previous study confirmed that psychological distress in patients is associated with advanced disease stage.<sup>[<xref rid="R34" ref-type="bibr">34</xref>]</sup> It may be because in the advanced stage of the tumor, the involvement of other parts of the body or vital organs, and the face of disease progression and uncertain prognosis, the patient&#x02019;s physical and mental burden is heavier, and it is difficult for them to carry out self-regulation effectively.<sup>[<xref rid="R35" ref-type="bibr">35</xref>]</sup> Therefore, caregivers should assess the SRF level in patients with advanced disease, effectively manage the symptoms of those with advanced tumors, provide health education for patients, and improve their poor psychological status.</p></sec><sec><title>
4.2.4. Association of the number of chemotherapy-related symptoms on SRF</title><p>Our data demonstrate that more patients with less than or equal to one of chemotherapy-related symptoms were included in the moderate SRF, borderline and low SRF, behavioral stabilization groups, consistent with previous studies.<sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup> Patients with multiple chemotherapy-related symptoms have poorer physical function and decreased body regulation.<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup> They not only needed to face the challenges posed by the disease itself but also needed to manage the effects of their treatment-related symptoms, which increase the adverse emotional experiences of patients and aggravate SRF.<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup> These findings suggest that clinical staff should target nursing interventions according to the type and number of patient symptoms, as well as improve the ability of patients to manage chemotherapy-related symptoms.</p></sec><sec sec-type="subjects"><title>
4.2.5. Association between whether or not the patient had undergone surgery for breast cancer and SRF</title><p>The results of this study indicate that patients who did not undergo breast cancer surgery were more likely to be categorized in the low SRF, behavioral stabilization group. After breast cancer surgery, the lack of secondary female characteristics makes patients dissatisfied with their image and prone to anxiety or depression.<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup> Surgical trauma leads to postoperative pain and other discomforts, affecting patients&#x02019; sleep quality and daily activities. Patients need regular functional exercises, and their SRF is heavy. Therefore, healthcare workers should assess patients&#x02019; physical and mental state who have undergone surgical treatment for breast cancer and intervene promptly. Healthcare professionals provide comprehensive treatment to patients with severe physical discomfort, explaining the importance of functional exercises and improving their confidence in recovery.</p></sec></sec><sec sec-type="subjects"><title>
4.3. Variation in activation scores among patients with different SRF profiles</title><p>Breast cancer is a long-term health challenge that requires patients to actively cope with disease progression and participate in disease treatment and management to achieve improved health outcomes.<sup>[<xref rid="R40" ref-type="bibr">40</xref>]</sup> Our results show that activation among patients with breast cancer undergoing chemotherapy was moderate, which aligns with the findings of Ma investigation<sup>[<xref rid="R41" ref-type="bibr">41</xref>]</sup> and suggests that activation needs to be improved in such patients. In this study, we found that patients with varying levels of SRF had different patient activation scores, as follows scores were highest in the low SRF, behavioral stabilization group, followed by the moderate SRF, borderline group, and lowest in the high SRF, cognitively weakened group, implying that SRF may influence patient activation. The theory of ego depletion<sup>[<xref rid="R42" ref-type="bibr">42</xref>]</sup> proposes that humans possess finite psychological energy and can only perform a limited number of self-control measures in the short term. In the disease management process, patients need to constantly self-regulate, for example, controlling emotions, adjusting lifestyles, and following medical advice. All of these activities consume patient psychological resources, leading to SRF, decreasing patient activation, and ultimately potentially affecting health outcomes. Healthcare professionals should prioritize patients with high levels of SRF, listen to their feelings, guide them to express their negative emotions in different ways, such as talking, writing, drawing, and work with patients to develop a specific and achievable health schedule, to enhance their self-management ability and confidence. For patients with less severe SRF, healthcare professionals should encourage them to maintain a good state of adaptation and further improve their confidence in actively coping with the disease. However, there have been few quantitative studies on the causal link between SRF and activation in individuals with breast cancer undergoing chemotherapy. More studies are needed to confirm this association in the future.</p></sec><sec><title>
4.4. Limitations</title><p>This study investigated only 315 patients with breast cancer undergoing chemotherapy at 2 tertiary hospitals in Sichuan Province, China, which is a relatively small sample size. In the future, cross-regional and large-sample surveys can be conducted, to build on the results of this study. Second, this was a quantitative study, and qualitative or mixed studies could be conducted in the future, to facilitate deep analysis of patient SRF experiences and their influencing factors.</p></sec></sec><sec><title>
5. Conclusion</title><p>In this study, we used latent profile analysis to classify patients with breast cancer undergoing chemotherapy into 3 SRF profiles: high SRF, cognitively weakened; moderate SRF, borderline; and low SRF, behavioral stabilization groups. Medical payment method, disease duration, disease stage, number of chemotherapy-related symptoms, and whether or not the patient had undergone surgery for breast cancer were factors that potentially influenced SRF profile. Further, patient activation levels varied across SRF profiles. Our data suggest that medical personnel should target interventions to improve patient activation based on their different SRF profiles.</p></sec><sec><title>Acknowledgments</title><p>The authors thank all the patients and staff who participated in this study.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Ying Yang, Li Li.</p><p><bold>Data curation:</bold> Jing Zhao, Li Li.</p><p><bold>Formal analysis:</bold> Jing Zhao, Yina Liu.</p><p><bold>Investigation:</bold> Ying Yang.</p><p><bold>Supervision:</bold> Li Li.</p><p><bold>Writing &#x02013; original draft:</bold> Ying Yang, Yina Liu.</p><p><bold>Writing &#x02013; review &#x00026; editing:</bold> Ying Yang, Li Li.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>aBIC</term><def><p>adjusted Bayesian information criterion</p></def></def-item><def-item><term>AIC</term><def><p>Akaike information criterion</p></def></def-item><def-item><term>BIC</term><def><p>Bayesian information criterion</p></def></def-item><def-item><term>BLRT</term><def><p>bootstrapped likelihood ratio test</p></def></def-item><def-item><term>LMR</term><def><p>Lo&#x02013;Mendell&#x02013;Rubin test</p></def></def-item><def-item><term>Log (L)</term><def><p>log-likelihood</p></def></def-item><def-item><term>PAM</term><def><p>patient activation measurem</p></def></def-item><def-item><term>SRF</term><def><p>self-regulatory fatigue</p></def></def-item><def-item><term>SRF-S</term><def><p>self-regulatory fatigue scale</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="COI-statement"><p>The authors have no funding and conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></fn><fn fn-type="other"><p>How to cite this article: Yang Y, Zhao J, Liu Y, Li L. A latent profile analysis of self-regulatory fatigue and its relationship with activation in patients receiving chemotherapy for breast carcinoma: An observational study. Medicine 2025;104:20(e42398).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.</article-title>
<source>CA Cancer J Clin</source>. <year>2024</year>;<volume>74</volume>:<fpage>229</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>RS</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>BF</given-names></name><etal/></person-group>. <article-title>Cancer incidence and mortality in China, 2022.</article-title>
<source>Chin J Oncol</source>. <year>2024</year>;<volume>46</volume>:<fpage>221</fpage>&#x02013;<lpage>31</lpage>. (in Chinese).</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>SM</given-names></name><name><surname>Tran</surname><given-names>HTT</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer.</article-title>
<source>Cancer</source>. <year>2024</year>;<volume>130</volume>:<fpage>2014</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">38319284</pub-id>
</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>R</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names><suffix>Jr</suffix></name><name><surname>O&#x02019;Connell</surname><given-names>N</given-names></name><etal/></person-group>; <collab>UPBEAT Study Team</collab>. <article-title>Hypertension severity and declines in left ventricular ejection fraction among women receiving adjuvant chemotherapy for breast cancer (WF-97415 UPBEAT).</article-title>
<source>Hypertension</source>. <year>2024</year>;<volume>81</volume>:<fpage>1365</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">38634292</pub-id>
</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kida</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>A</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.</article-title>
<source>Breast Cancer</source>. <year>2024</year>;<volume>31</volume>:<fpage>409</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">38453739</pub-id>
</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milam</surname><given-names>EC</given-names></name><name><surname>Rangel</surname><given-names>LK</given-names></name><name><surname>Pomeranz</surname><given-names>MK</given-names></name></person-group>. <article-title>Dermatologic sequelae of breast cancer: from disease, surgery, and radiation.</article-title>
<source>Int J Dermatol</source>. <year>2021</year>;<volume>60</volume>:<fpage>394</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">33226140</pub-id>
</mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nes</surname><given-names>LS</given-names></name><name><surname>Ehlers</surname><given-names>SL</given-names></name><name><surname>Whipple</surname><given-names>MO</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name></person-group>. <article-title>Self-regulatory fatigue in chronic multisymptom illnesses: scale development, fatigue, and self-control.</article-title>
<source>J Pain Res</source>. <year>2013</year>;<volume>6</volume>:<fpage>181</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23526193</pub-id>
</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumeister</surname><given-names>RF</given-names></name><name><surname>Bratslavsky</surname><given-names>E</given-names></name><name><surname>Muraven</surname><given-names>M</given-names></name><name><surname>Tice</surname><given-names>DM</given-names></name></person-group>. <article-title>Ego depletion: is the active self a limited resource?</article-title>
<source>J Pers Soc Psychol</source>. <year>1998</year>;<volume>74</volume>:<fpage>1252</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">9599441</pub-id>
</mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>DD</given-names></name><name><surname>Altman</surname><given-names>M</given-names></name><name><surname>Boswell</surname><given-names>RG</given-names></name><name><surname>Kelley</surname><given-names>WM</given-names></name><name><surname>Heatherton</surname><given-names>TF</given-names></name></person-group>. <article-title>Self-regulatory depletion enhances neural responses to rewards and impairs top-down control.</article-title>
<source>Psychol Sci</source>. <year>2013</year>;<volume>24</volume>:<fpage>2262</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">24026225</pub-id>
</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>LW</given-names></name></person-group>. <article-title>Positivity of self-management in patients with gynaecological malignant tumour undergoing chemotherapy: current status, influencing factors, and strategies countermeasures of self-management enthusiasm in gynecological malignant tumor patients undergoing chemotherapy.</article-title>
<source>Mod Clin Nurs</source>. <year>2023</year>;<volume>22</volume>:<fpage>38</fpage>&#x02013;<lpage>45</lpage>. (in Chinese).</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hibbard</surname><given-names>JH</given-names></name><name><surname>Mahoney</surname><given-names>ER</given-names></name><name><surname>Stockard</surname><given-names>J</given-names></name><name><surname>Tusler</surname><given-names>M</given-names></name></person-group>. <article-title>Development and testing of a short form of the patient activation measure.</article-title>
<source>Health Serv Res</source>. <year>2005</year>;<volume>40</volume>:<fpage>1918</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">16336556</pub-id>
</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>UN</given-names></name><name><surname>Lloyd</surname><given-names>J</given-names></name><name><surname>Hosseinzadeh</surname><given-names>H</given-names></name><name><surname>Baral</surname><given-names>KP</given-names></name><name><surname>Bhatta</surname><given-names>N</given-names></name><name><surname>Harris</surname><given-names>MF</given-names></name></person-group>. <article-title>Self-management practice, associated factors and its relationship with health literacy and patient activation among multi-morbid COPD patients from rural Nepal.</article-title>
<source>BMC Public Health</source>. <year>2020</year>;<volume>20</volume>:<fpage>300</fpage>.<pub-id pub-id-type="pmid">32143673</pub-id>
</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keen</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Oruche</surname><given-names>UM</given-names></name><name><surname>Mazurenko</surname><given-names>O</given-names></name><name><surname>Burke Draucker</surname><given-names>C</given-names></name></person-group>. <article-title>Patient activation of persons with opioid use disorder in intensive outpatient treatment.</article-title>
<source>J Am Psychiatr Nurses Assoc</source>. <year>2024</year>;<volume>30</volume>:<fpage>333</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">35581715</pub-id>
</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Diabetes distress and disordered eating behaviors in youth with type 1 diabetes: the mediating role of self-regulatory fatigue and the moderating role of resilience.</article-title>
<source>J Eat Disord</source>. <year>2023</year>;<volume>11</volume>:<fpage>123</fpage>.<pub-id pub-id-type="pmid">37481574</pub-id>
</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>WQ</given-names></name></person-group>. <article-title>Promoting high-quality development of cancer control and prevention to effectively reduce the burden of cancer.</article-title>
<source>China Cancer</source>. <year>2024</year>;<volume>33</volume>:<fpage>1</fpage>&#x02013;<lpage>5</lpage>. (in Chinese).</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronin</surname><given-names>RM</given-names></name><name><surname>Dorner</surname><given-names>TL</given-names></name><name><surname>Utrankar</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Increased patient activation is associated with fewer emergency room visits and hospitalizations for pain in adults with sickle cell disease.</article-title>
<source>Pain Med</source>. <year>2019</year>;<volume>20</volume>:<fpage>1464</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">30329108</pub-id>
</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shnaigat</surname><given-names>M</given-names></name><name><surname>Downie</surname><given-names>S</given-names></name><name><surname>Hosseinzadeh</surname><given-names>H</given-names></name></person-group>. <article-title>Effectiveness of patient activation interventions on chronic obstructive pulmonary disease self-management outcomes: a systematic review.</article-title>
<source>Aust J Rural Health</source>. <year>2022</year>;<volume>30</volume>:<fpage>8</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">35034409</pub-id>
</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussein</surname><given-names>WF</given-names></name><name><surname>Bennett</surname><given-names>PN</given-names></name><name><surname>Abra</surname><given-names>G</given-names></name><name><surname>Watson</surname><given-names>E</given-names></name><name><surname>Schiller</surname><given-names>B</given-names></name></person-group>. <article-title>Integrating patient activation into dialysis care.</article-title>
<source>Am J Kidney Dis</source>. <year>2022</year>;<volume>79</volume>:<fpage>105</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">34461165</pub-id>
</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuhuan</surname><given-names>Z</given-names></name><name><surname>Pengyue</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The association between academic stress, social support, and self-regulatory fatigue among nursing students: a cross-sectional study based on a structural equation modelling approach.</article-title>
<source>BMC Med Educ</source>. <year>2022</year>;<volume>22</volume>:<fpage>789</fpage>.<pub-id pub-id-type="pmid">36376814</pub-id>
</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name></person-group>. <article-title>Effect of self-control on health promotion behavior in patients with coronary heart disease: mediating effect of ego-depletion.</article-title>
<source>Psychol Health Med</source>. <year>2022</year>;<volume>27</volume>:<fpage>1268</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">33813978</pub-id>
</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Shan</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Dietary adherence, self-regulatory fatigue and trait self-control among chinese patients with peritoneal dialysis: a cross-sectional study.</article-title>
<source>Patient Prefer Adherence</source>. <year>2021</year>;<volume>15</volume>:<fpage>443</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">33658768</pub-id>
</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name></person-group>. <article-title>Validity and reliability of the Chinese version of the self-regulatory fatigue scale in young adults.</article-title>
<source>Chin Ment Health J</source>. <year>2015</year>;<volume>29</volume>:<fpage>290</fpage>&#x02013;<lpage>4</lpage>. (in Chinese).</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>YF</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group>. <article-title>Reliability and validity of the Chinese version of patient activation measure.</article-title>
<source>Chin J Mod Nurs</source>. <year>2018</year>;<volume>24</volume>:<fpage>3009</fpage>&#x02013;<lpage>15</lpage>. (in Chinese).</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilberdink</surname><given-names>CE</given-names></name><name><surname>van Zuiden</surname><given-names>M</given-names></name><name><surname>Olff</surname><given-names>M</given-names></name><name><surname>Roseboom</surname><given-names>TJ</given-names></name><name><surname>de Rooij</surname><given-names>SR</given-names></name></person-group>. <article-title>The impact of adversities across the lifespan on psychological symptom profiles in late adulthood: a latent profile analysis.</article-title>
<source>J Dev Orig Health Dis</source>. <year>2023</year>;<volume>14</volume>:<fpage>508</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">37477375</pub-id>
</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podsakoff</surname><given-names>PM</given-names></name><name><surname>MacKenzie</surname><given-names>SB</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Podsakoff</surname><given-names>NP</given-names></name></person-group>. <article-title>Common method biases in behavioral research: a critical review of the literature and recommended remedies.</article-title>
<source>J Appl Psychol</source>. <year>2003</year>;<volume>88</volume>:<fpage>879</fpage>&#x02013;<lpage>903</lpage>.<pub-id pub-id-type="pmid">14516251</pub-id>
</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>ZH</given-names></name><name><surname>Zhang</surname><given-names>RX</given-names></name><etal/></person-group>. <article-title>Mediating effect of social anxiety and stigma on family caring and loneliness in breast cancer patients.</article-title>
<source>Chin Nurs Res</source>. <year>2024</year>;<volume>38</volume>:<fpage>571</fpage>&#x02013;<lpage>6</lpage>. (in Chinese).</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name></person-group>. <article-title>Factors associated with self-regulatory fatigue in Chinese older patients with coronary heart disease: a cross-sectional survey.</article-title>
<source>Patient Prefer Adherence</source>. <year>2023</year>;<volume>17</volume>:<fpage>941</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">37033294</pub-id>
</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><collab>Committee of Breast Cancer Society, China Anti-Cancer Association</collab>. <article-title>Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer (2024 edition).</article-title>
<source>Chin Oncol</source>. <year>2024</year>;<volume>34</volume>:<fpage>316</fpage>&#x02013;<lpage>34</lpage>. (in Chinese).</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>HX</given-names></name></person-group>. <article-title>Self-regulatory fatigue and its influencing factors in convalescent stroke patients.</article-title>
<source>J Nurs Sci</source>. <year>2023</year>;<volume>38</volume>:<fpage>10</fpage>&#x02013;<lpage>4</lpage>. (in Chinese).</mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>N</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group>. <article-title>Status quo of self-regulation fatigue among patients with rheumatoid arthritis and its influencing factors.</article-title>
<source>Mil Nurs</source>. <year>2022</year>;<volume>39</volume>:<fpage>44</fpage>&#x02013;<lpage>7</lpage>. (in Chinese).</mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>J</given-names></name></person-group>. <article-title>Evidence from the China family panel studies survey on the effect of integrating the basic medical insurance system for urban and rural residents on the health equity of residents: difference-in-differences analysis.</article-title>
<source>JMIR Public Health Surveill</source>. <year>2024</year>;<volume>10</volume>:<fpage>e50622</fpage>.<pub-id pub-id-type="pmid">38815256</pub-id>
</mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Lang</surname><given-names>YM</given-names></name></person-group>. <article-title>Status quo and influencing factors of self-regulatory fatigue in type 2 diabetes patients.</article-title>
<source>J Nurs Sci</source>. <year>2023</year>;<volume>38</volume>:<fpage>73</fpage>&#x02013;<lpage>6</lpage>. (in Chinese).</mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Song</surname><given-names>XL</given-names></name><name><surname>Qie</surname><given-names>SW</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>YQ</given-names></name></person-group>. <article-title>Status quo and influencing factors of self-regulation fatigue in peritoneal dialysis patients.</article-title>
<source>Chin Nurs Res</source>. <year>2022</year>;<volume>36</volume>:<fpage>4259</fpage>&#x02013;<lpage>62</lpage>. (in Chinese).</mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aquil</surname><given-names>A</given-names></name><name><surname>El Kherchi</surname><given-names>O</given-names></name><name><surname>El Azmaoui</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Predictors of mental health disorders in women with breast and gynecological cancer after radical surgery: a cross-sectional study.</article-title>
<source>Ann Med Surg (Lond)</source>. <year>2021</year>;<volume>65</volume>:<fpage>102278</fpage>.<pub-id pub-id-type="pmid">33948163</pub-id>
</mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>JH</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>MY</given-names></name><name><surname>Mo</surname><given-names>YM</given-names></name></person-group>. <article-title>The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.</article-title>
<source>Breast Cancer</source>. <year>2024</year>;<volume>31</volume>:<fpage>417</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">38561479</pub-id>
</mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Factors influencing self-regulatory fatigue in patients undergoing chemotherapy for gynecologic cancer: a cross-sectional study.</article-title>
<source>Front Psychiatry</source>. <year>2024</year>;<volume>15</volume>:<fpage>1273151</fpage>.<pub-id pub-id-type="pmid">38726383</pub-id>
</mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Amouri</surname><given-names>FM</given-names></name><name><surname>Badrasawi</surname><given-names>M</given-names></name></person-group>. <article-title>Taste alteration and its relationship with nutritional status among cancer patients receiving chemotherapy, cross-sectional study.</article-title>
<source>PLoS One</source>. <year>2024</year>;<volume>19</volume>:<fpage>e0302990</fpage>.<pub-id pub-id-type="pmid">38723006</pub-id>
</mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YX</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><etal/></person-group>. <article-title>Status quo and its influencing factors of self-regulating fatigue in nasopharyngeal carcinoma patients undergoing radiotherapy and chemotherapy.</article-title>
<source>Mil Nurs</source>. <year>2021</year>;<volume>38</volume>:<fpage>17</fpage>&#x02013;<lpage>20</lpage>. (in Chinese).</mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breidenbach</surname><given-names>C</given-names></name><name><surname>Heidkamp</surname><given-names>P</given-names></name><name><surname>Hiltrop</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Prevalence and determinants of anxiety and depression in long-term breast cancer survivors.</article-title>
<source>BMC Psychiatry</source>. <year>2022</year>;<volume>22</volume>:<fpage>101</fpage>.<pub-id pub-id-type="pmid">35139815</pub-id>
</mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>D</given-names></name><name><surname>Mayer</surname><given-names>DK</given-names></name><name><surname>Fielding</surname><given-names>R</given-names></name><etal/></person-group>; <collab>Global Partners for Self-Management in Cancer</collab>. <article-title>Management of cancer and health after the clinic visit: a call to action for self-management in cancer care.</article-title>
<source>J Natl Cancer Inst</source>. <year>2021</year>;<volume>113</volume>:<fpage>523</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">32525530</pub-id>
</mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>HL</given-names></name><name><surname>Wang</surname><given-names>SJ</given-names></name><name><surname>Gao</surname><given-names>YP</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name></person-group>. <article-title>The self-management activation and associated factors in young and middle-aged patients with thyroid cancer after surgery.</article-title>
<source>J Nurs Sci</source>. <year>2023</year>;<volume>38</volume>:<fpage>27</fpage>&#x02013;<lpage>30</lpage>. (in Chinese).</mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumeister</surname><given-names>RF</given-names></name><name><surname>Gailliot</surname><given-names>M</given-names></name><name><surname>DeWall</surname><given-names>CN</given-names></name><name><surname>Oaten</surname><given-names>M</given-names></name></person-group>. <article-title>Self-regulation and personality: how interventions increase regulatory success, and how depletion moderates the effects of traits on behavior.</article-title>
<source>J Pers</source>. <year>2006</year>;<volume>74</volume>:<fpage>1773</fpage>&#x02013;<lpage>801</lpage>.<pub-id pub-id-type="pmid">17083666</pub-id>
</mixed-citation></ref></ref-list></back></article>